Two Sigma Advisers LP Decreases Stock Position in Celcuity Inc. (NASDAQ:CELC)

Two Sigma Advisers LP lowered its stake in Celcuity Inc. (NASDAQ:CELC) by 6.9% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 51,200 shares of the company’s stock after selling 3,800 shares during the quarter. Two Sigma Advisers LP owned about 0.14% of Celcuity worth $670,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Summit Investment Advisors Inc. lifted its stake in Celcuity by 49.5% in the 4th quarter. Summit Investment Advisors Inc. now owns 3,421 shares of the company’s stock worth $45,000 after purchasing an additional 1,132 shares in the last quarter. Aquatic Capital Management LLC bought a new position in shares of Celcuity in the 4th quarter valued at about $50,000. The Manufacturers Life Insurance Company bought a new position in shares of Celcuity in the 4th quarter valued at about $142,000. Bleakley Financial Group LLC bought a new position in shares of Celcuity in the 4th quarter valued at about $146,000. Finally, Trexquant Investment LP bought a new position in shares of Celcuity in the 4th quarter valued at about $152,000. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Celcuity Stock Performance

Celcuity stock opened at $11.94 on Wednesday. The company has a debt-to-equity ratio of 0.65, a current ratio of 10.35 and a quick ratio of 10.36. Celcuity Inc. has a 1-year low of $7.58 and a 1-year high of $19.77. The firm has a market capitalization of $452.12 million, a P/E ratio of -4.57 and a beta of 0.56. The company’s 50-day moving average is $10.24 and its 200 day moving average is $11.31.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.86) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.95) by $0.09. Research analysts forecast that Celcuity Inc. will post -2.62 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $27.00 price target on shares of Celcuity in a report on Monday, May 19th. Needham & Company LLC reaffirmed a “buy” rating and issued a $29.00 price target on shares of Celcuity in a report on Thursday, May 15th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Celcuity has a consensus rating of “Buy” and an average price target of $30.80.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.